Molecular Mechanisms of Epigallocatechin-3-Gallate for Prevention of Chronic Kidney Disease and Renal Fibrosis: Preclinical Evidence
Open Access
- 29 August 2019
- journal article
- research article
- Published by Elsevier BV in Current Developments in Nutrition
- Vol. 3 (9), nzz101
- https://doi.org/10.1093/cdn/nzz101
Abstract
Chronic kidney disease (CKD) is a common public health problem worldwide characterized by gradual decline of renal function over months/years accompanied by renal fibrosis and failure in tissue wound healing after sustained injury. Patients with CKD frequently present with profound signs/symptoms that require medical treatment, mostly culminating in hemodialysis and renal transplantation. To prevent CKD more efficiently, there is an urgent need for better understanding of the pathogenic mechanisms and molecular pathways of the disease pathogenesis and progression, and for developing novel therapeutic targets. Recently, several lines of evidence have shown that epigallocatechin-3-gallate (EGCG), an abundant phytochemical polyphenol derived from Camellia sinensis, might be a promising bioactive compound for prevention of CKD development/progression. This review summarizes current knowledge of molecular mechanisms underlying renoprotective roles of EGCG in CKD based on available preclinical evidence (from both in vitro and in vivo animal studies), particularly its antioxidant property through preservation of mitochondrial function and activation of Nrf2 (nuclear factor erythroid 2-related factor 2)/HO-1 (heme oxygenase-1) signaling, anti-inflammatory activity, and protective effect against epithelial mesenchymal transition. Finally, future perspectives, challenges, and concerns regarding its clinical use in CKD and renal fibrosis are discussed.Keywords
Funding Information
- Thailand Research Fund (IRN60W0004, IRG5980006)
- Medicine Siriraj Hospital
This publication has 103 references indexed in Scilit:
- Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndromeBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Oxidative stress, anti‐oxidant therapies and chronic kidney diseaseNephrology, 2012
- NF-κB, the first quarter-century: remarkable progress and outstanding questionsGenes & Development, 2012
- Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activationFree Radical Biology & Medicine, 2011
- Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cellsCellular & Molecular Immunology, 2010
- The Nuclear Factor NF- B Pathway in InflammationCold Spring Harbor Perspectives in Biology, 2009
- The IKK Complex, a Central Regulator of NF- B ActivationCold Spring Harbor Perspectives in Biology, 2009
- Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1Biochemical Journal, 2009
- Regulating the Age-Related Oxidative Damage, Mitochondrial Integrity, and Antioxidative Enzyme Activity in Fischer 344 Rats by Supplementation of the Antioxidant Epigallocatechin-3-GallateRejuvenation Research, 2008
- Keap1 Recruits Neh2 through Binding to ETGE and DLG Motifs: Characterization of the Two-Site Molecular Recognition ModelMolecular and Cellular Biology, 2006